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Abstract
Acute mountain sickness (AMS) occurs when there is failure of acclimatisation to 
high altitude. The aim of this study was to describe the relationship between physi-
ological variables and the incidence of AMS during ascent to 5300 m. A total of 332 
lowland- dwelling volunteers followed an identical ascent profile on staggered treks. 
Self- reported symptoms of AMS were recorded daily using the Lake Louise score (mild 
3– 4; moderate- severe ≥5), alongside measurements of physiological variables (heart 
rate, respiratory rate (RR), peripheral oxygen saturation (SpO2) and blood pressure) 
before and after a standardised Xtreme Everest Step- Test (XEST). The overall occur-
rence of AMS among participants was 73.5% (23.2% mild, 50.3% moderate– severe). 
There was no difference in gender, age, previous AMS, weight or body mass index 
between participants who developed AMS and those who did not. Participants who had 
not previously ascended >5000 m were more likely to get moderate- to- severe AMS. 
Participants who suffered moderate- to- severe AMS had a lower resting SpO2 at 3500 m 
(88.5 vs. 89.6%, p = 0.02), while participants who suffered mild or moderate- to- severe 
AMS had a lower end- exercise SpO2 at 3500 m (82.2 vs. 83.8%, p = 0.027; 81.5 vs. 
83.8%, p < 0.001 respectively). Participants who experienced mild AMS had lower 
end- exercise RR at 3500 m (19.2 vs. 21.3, p = 0.017). In a multi- variable regression 
model, only lower end- exercise SpO2 (OR 0.870, p < 0.001) and no previous exposure 
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1 |  INTRODUCTION
Prior to the COVID- 19 pandemic, increasing numbers of peo-
ple were travelling to high altitude, and it is likely that these 
numbers will return when domestic and international travel is 
freely available once again. During ascent to altitude, exposure 
to hypobaric hypoxia due to the reduction in partial pressure 
of oxygen occurs with increasing elevation. Acclimatisation 
permits adaptation to hypoxia, but failure of this process can 
result in acute mountain sickness (AMS). AMS is a syndrome 
that is defined by the presence of a headache in combination 
with other symptoms including dizziness, fatigue, loss of ap-
petite and insomnia. AMS is relatively common among trek-
kers, affecting 36.7% of participants at 3658 m and as many 
as 75% of participants attempting Mount Kilimanjaro (5984 m; 
Gonggalanzi et al., 2016; Karinen et al., 2008). The Lake Louise 
scoring system was devised to aid in the diagnosis of AMS, pro-
vide a subjective scale for the description of symptoms and to 
facilitate research (Roach et al., 1993). The system was revised 
in 2018, by the removal of one scoring domain (Roach, 2018). 
The precise pathophysiology underlying AMS remains elusive, 
however, a number of hypotheses exist that may explain why 
the hypobaric hypoxia experienced at high altitude causes these 
symptoms (Wilson et al., 2009). SEVERAL risk factors for sus-
ceptibility to AMS have been previously identified, although 
published data have been conflicting; these include a history of 
previous AMS, younger age, female gender, rapid ascent, obe-
sity and increased exertion (Hackett & Roach, 2001; Honigman 
et al., 1993; MacInnis et al., 2013; Richalet et al., 2012).
Results from studies attempting to predict which indi-
viduals will suffer from AMS in simulated altitude based 
on objective physiological measures have been inconsis-
tent (Burtscher et al., 2008). The largest prospective co-
hort study to assess physiological risk factors for AMS 
using a hypoxic pre- travel exercise test showed that high 
delta peripheral oxygen saturation (SpO2; beginning to 
end of exercise) and low ventilatory response to exercise 
were independent predictors of severe high- altitude illness 
(Richalet et al., 2012). Additional risk factors identified 
were ascent >400  m per day, previous history of severe 
high- altitude illness and previous history of migraine. 
Other studies assessing the use of resting SpO2 measure-
ments to predict AMS at real or simulated altitude have 
been conflicting with some studies reporting an associa-
tion between these two measures (Burtscher et al., 2004; 
Faulhaber et al., 2014; Guo et al., 2014; Karinen et al., 
2010; Mandolesi et al., 2014), while other studies have 
not (Chen et al., 2012; Leichtfried et al., 2015; O’Connor 
et al., 2004; Wagner et al., 2012).
The aim of the current study was to describe, in a large 
cohort of healthy lowland- dwelling volunteers, the rela-
tionship between simple physiological variables, mea-
sured before and after a standardised exercise protocol 
and the incidence of AMS during ascent to 5300 m fol-
lowing an identical ascent profile. We hypothesised that 
a greater decline in SpO2 following exercise at an early 
stage of ascent would be seen in those individuals who 
developed AMS.
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to altitude >5000 m (OR 2.740, p- value 0.003) predicted the development of moderate- 
to- severe AMS. The Xtreme Everest Step- Test offers a simple, reproducible field test to 
help predict AMS, albeit with relatively limited predictive precision.
K E Y W O R D S
altitude, altitude sickness, exercise, hypoxia
Key points
• We evaluated the performance of a simple exercise challenge at altitude (the 
Xtreme Everest Step- Test) in predicting acute mountain sickness (AMS) on a trek 
to Everest Base Camp (5300 m).
• The overall occurrence of AMS during the trek (using the 1993 Lake Louise score 
threshold of ≥3) was high (73.5%).
• Participant characteristics previously shown to predict AMS (gender, age, weight 
and history of AMS) were not related to the development of AMS in this study.
• Lower peripheral oxygen saturation (SpO2) following the Xtreme Everest Step- 
Test at 3500 m and no previous exposure to altitude >5000 m predicted the de-
velopment of moderate- to- severe AMS (1993 Lake Louise score threshold of ≥5) 
during the trek.
• The Xtreme Everest Step- Test offers a simple, reproducible field test to contribute 
towards the prediction of AMS, albeit with relatively limited predictive precision.
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2 |  METHODS
2.1 | Study participants
Participants were part of three separate research expeditions 
that took place over a 6- year period: Caudwell Xtreme Everest 
(2007) (Levett et al., 2010), Caudwell Xtreme Everest 2009 
(2009) (Holloway et al., 2014) and Xtreme Everest 2 (2013) 
(Gilbert- Kawai et al., 2015). They were aged 18  years or 
above, permanently resident at low altitude (<1000 m) and 
were required to pass a two- stage health screen by experi-
enced expedition doctors. Ethical approval was granted by the 
University College London Research Ethics Committee and 
written informed consent was obtained from all participants.
2.2 | Study setting
Details of the trek to Everest base camp (EBC; 5300  m) 
have been published previously (Gilbert- Kawai et al., 2015; 
Levett et al., 2010). All participants underwent baseline 
testing, including the Xtreme Everest Step- Test (XEST), 
prior to ascent to high altitude, then undertook an 11- day 
ascent to EBC and remained there for two further days 
(Figure 1). All participants followed an identical ascent 
profile to EBC, with the exception of 14 individuals who 
deviated for medical or personal reasons. Baseline testing 
was undertaken in London (75 m); however, 14 participants 
undertook sea level testing in Kathmandu (1300 m) due to 
logistical difficulties getting to London. Previous stud-
ies have confirmed a similar SpO2 between sea level and 
Kathmandu (Grant et al., 2002). Acetazolamide was not 
taken prophylactically by any participant, but was admin-
istered to those showing symptoms of severe AMS, at the 
discretion of the expedition medical team.
2.3 | Physiological measurements and 
AMS scoring
Each morning participants completed a diary containing the 
Lake Louise scoring system, and then undertook a short ex-
ercise protocol, recording measurements according to writ-
ten instructions provided to them (Roach et al., 1993). As 
expeditions took place in 2007, 2009 and 2013, data were 
collected and analysed using the original Lake Louise scor-
ing system which included the sleep component of the AMS 
score. The measurements and exercise challenge were con-
ducted at approximately the same time each day, first thing 
in the morning prior to consuming any food or caffeine. The 
physiological measurements consisted of resting SpO2 and 
heart rate (HR; Nonin Onyx II 9550, Nonin Medical Inc), 
respiratory rate (RR) that was counted by a fellow partici-
pant and blood pressure (BP) recorded as the mean of three 
measurements (Omron Intellisense M7, Omron Healthcare 
Europe B.V.). All resting measurements were taken after par-
ticipants had been resting (seated) for 5  min (Levett et al., 
2010). Following resting measurements, the XEST was un-
dertaken, comprising of 2  min of stepping onto and off a 
20 cm high step, at a rate of one step up or down per second, 
guided by a metronome (Levett et al., 2010). All physiologi-
cal measurements (with the exception of blood pressure) were 
repeated during the minute immediately after the XEST was 
completed (end- exercise measures). Two Lake Louise score 
thresholds were used to determine the presence of AMS; 3– 4 
was considered as mild, while ≥5 was considered moderate 
to severe. Only scores reaching these thresholds in the pres-
ence of a headache were deemed to indicate AMS. No AMS 
was determined by a score of ≤2 or the absence of a headache 
regardless of the score.
2.4 | Data analysis
Data were tested for normality using histograms, and de-
scribed accordingly. The physiological data used for the 
primary analysis were from the first morning after arrival at 
Namche Bazaar (3500 m), as a steep ascent (from 2800 m 
to 3500 m in 1- day) is required to reach this altitude. This 
ascent occurs early in the trek (day 2) and Namche Bazaar is 
often the first location at which AMS occurs. Independent 
t- tests and chi- squared tests were used for continuous and 
categorical variables respectively. Occasionally partici-
pants were unable to undertake the diary test due to illness 
F I G U R E  1  The planned ascent profile for all participants. Daily 
ascent profile to altitude. In summary, participants went by airplane 
from Kathmandu (1300 m) to Lukla (2860 m), then ascended on foot. 
Rest days were inserted into the schedule to allow other experiments 
to be performed, and to reduce the anticipated incidence of AMS by 
allowing additional time for acclimatisation (Gilbert- Kawai et al., 
2015; Levett et al., 2010)
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or data were incomplete. On these occasions, physiological 
data from the following day at 3500 m (trek day 3) were 
used instead (n = 9). Sensitivity analyses were undertaken 
to test the robustness of the results when these participants 
were removed, and it demonstrated no significant impact 
on results.
A univariate logistic regression analysis was performed 
for each physiological and demographic variable. Variables 
with p  <  0.15 were included in a multiple logistic regres-
sion analysis for moderate- to- severe AMS. A ROC curve was 
performed on the predicted probabilities from the logistic re-
gression to assess the goodness of fit.
All data were analysed using IBM SPSS Version 24 (IBM 
Corp. released 2013. IBM SPSS Statistics for Windows, Version 
23. IBM Corp.). Statistical significance was taken as p < 0.05.
3 |  RESULTS
3.1 | Participant characteristics
The total number of participants across the three expeditions 
was 441, with 332 eligible for inclusion in this study (Figure 2). 
A total of 64 participants were excluded from this analysis 
F I G U R E  2  Flow diagram detailing the 
number of participants included in the final 
analysis. EBC, Everest Base Camp
   | 5 of 12COBB et al.
because they were high- altitude residents (Sherpa) and 24 be-
cause they were Xtreme Everest investigators who followed 
an alternative (slightly slower) ascent profile. Fourteen par-
ticipants had a slightly different ascent profile from the main 
cohort due to illness or personal circumstances, and this re-
sulted in them spending additional days at a lower altitude. Of 
these fourteen, six had AMS, two had diarrhoea and vomiting, 
two had respiratory tract infections, one stayed behind with an 
unwell relative and in three instances the reason could not be 
determined.
In the study cohort, 56.9% of participants were men and 
the mean age of participants was 43.1  years (Table 1). The 
percentage of participants who had previously been exposed 
to high altitude (>3500 m) was 48.5% (n = 160), and of those 
6.1% (n = 20) self- reported that they had previously experi-
enced AMS.
3.2 | Acute mountain sickness
Overall, 244 of 332 participants developed AMS (Lake 
Louise score of ≥3 with presence of headache) at any 
point during the expedition (73.5%, 95% confidence 
interval (CI), 68.7– 78.2%). A total of 77 developed 
mild AMS (23.2%, CI 18.6– 27.8%) and 167 developed 
moderate- to- severe AMS (50.3%, 95% CI, 44.9– 55.7%). 
The number of participants with AMS at each day during 
the trek is shown in Figure 3. There was no difference 
in gender, age, previous AMS, weight or BMI between 
participants who developed AMS and those who did 
not (Table 2). Participants who developed mild AMS 
were taller than those who did not (174.3 vs. 170.8 cm, 
p = 0.018). The overall incidence of acetazolamide use 
for treatment of AMS was 19.0% (n = 63). Participants 
requiring acetazolamide for treatment of AMS were 
older than those who did not require this medication 
(47.0 years vs. 42.2 years, p = 0.015). Participants who 
had not previously ascended >5000 m were more likely 
to get moderate- to- severe AMS (p = 0.006).
3.3 | Physiological data
Changes in measured physiological variables on each day 
of the trek are shown in Figure 4. SpO2 decreased both at 
rest and following exercise as altitude was gained. There was 
an increase in resting HR, resting RR and end- exercise RR 
throughout the ascent, along with an initial increase followed 
by a decrease in end- exercise HR. There was a small rise in 
systolic and diastolic BP throughout the trek.








Age Mean (95% CI) 44.1 (42.1– 46.2) 41.8 (39.6– 44.0) 43.1 (41.6– 44.6)
Height (cm) Mean (95% CI) 177.3 (176.2– 178.5) 165.6 (164.5– 166.7) 172.3 (171.3– 173.3)
Weight (Kg) Mean (95% CI) 80.8 (79.0– 82.6) 65.3 (63.7– 66.9) 74.1 (72.6– 75.6)
BMI Mean (95% CI) 25.7 (25.2– 26.1) 23.8 (23.3– 24.3) 24.9 (24.5– 25.2)
Previous altitude 3500– 5000 m n (% yes) 44 (23.4%) 40 (28.2%) 84 (25.5%)
Previous altitude >5000 m n (% yes) 49 (26.1%) 27 (19.0%) 76 (23.0%)
Previous AMS n (% yes) 9 (4.8%) 11 (7.8%) 20 (6.1%)
F I G U R E  3  Incidence of acute 
mountain sickness by trek day. LLS, Lake 
Louise score
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3.4 | AMS and physiological measures at 
concurrent altitudes
Physiological data collected at 3500  m and 5300  m are 
presented in Tables 3 and 4, respectively, according to 
participants’ AMS categorisation. At 3500  m, partici-
pants who developed mild AMS had lower end- exercise 
SpO2 (81.1 vs. 82.8%, p = 0.016) than those who did not, 
while those who developed moderate- to- severe AMS 









































































































































































































































































































































































































































































































































































































F I G U R E  4  Overall mean (±SEM) change in measured 
physiological variables in all participants during ascent to high 
altitude. Solid line = at rest, pre- exercise; dotted line = at end of 
exercise. Blood pressure was only measured at rest, prior to exercise
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and lower end- exercise SpO2 (80.7 vs. 82.8%, p = 0.007; 
Table 3). Resting heart rate was also higher in those with 
moderate- to- severe AMS (79.0 vs. 73.4 beats per minute, 
p = 0.015) at 3500 m than those with no AMS. At 5300 m, 
participants with mild AMS had a lower resting and end- 
exercise SpO2 than those who did not (76.0 vs. 79.0%, 
p  =  0.005 and 71.3 vs. 73.8%, p  =  0.003 respectively). 
Similarly, those with moderate- to- severe AMS also had 
a lower resting and end- exercise SpO2 than those who 
did not (77.3 vs. 79.0%, p  =  0.022 and 71.7 vs. 73.8%, 
p = 0.007 respectively; Table 4).
3.5 | AMS and physiological measures from 
3500 m
Participants who suffered moderate- to- severe AMS at any 
point during the trek had a lower resting SpO2 at 3500 m; 
Total n = 329
No AMS at 
3500 m
n = 241 (73.3%)
AMS (LLS 3– 4) at 
3500 m
n = 49 (26.7%)
AMS (LLS ≥5) at 
3500 m
n = 39 (11.9%)




82.8 (82.2– 83.3) 81.1* (79.9– 82.3) 80.7* (79.4– 82.0)
SpO2 delta (%) −6.6 (6.1– 7.1) −7.6 (6.4– 8.8) −7.0 (5.7– 8.2)





123.8 (118.5– 129.2) 130.1 (124.5– 135.8)
HR delta (bpm) 51.7 (49.4– 53.9) 48.0 (41.8– 54.2) 51.2 (47.1– 55.2)
RR resting (bpm) 13.5 (13.0– 14.0) 12.9 (12.0– 13.9) 13.9 (12.7– 15.1)
RR exercise 
(bpm)
20.2 (19.4– 20.9) 19.6 (18.1– 21.1) 20.9 (19.4– 22.4)





132.4 (128.2– 136.5) 134.7 (129.9– 139.4)
BP diastolic 
(mmHg)
83.7 (82.7– 84.8) 83.2 (80.6– 85.9) 83.7 (81.0– 86.5)
Note: Delta signifies the difference between resting and exercise values. Independent t- tests for continuous 
(mean, 95% confidence interval) variables.
*p ≤ 0.05. 
T A B L E  3  Physiological and AMS data 
from 3500 m (Namche Bazaar)
Total n = 319
No AMS at 5300 m
n = 217 (68.0%)
AMS (LLS 3– 4) at 
5300 m
n = 45 (14.1%)
AMS (LLS ≥5) at 
5300 m
n = 57 (17.9%)
SpO2 resting (%) 79.0 (78.4– 79.7) 76.0
* (74.1– 78.0) 77.3* (75.9– 78.7)
SpO2 exercise (%) 73.8 (73.1– 74.5) 71.3
* (69.8– 72.9) 71.7* (70.3– 73.1)
SpO2 delta (%) −5.2 (4.6– 5.8) −4.6 (2.9– 6.3) −5.6 (4.1– 7.1)
HR resting (bpm) 77.4 (75.4– 79.3) 78.0 (73.8– 82.3) 79.0 (75.5– 82.6)
HR exercise (bpm) 119.2 (116.3– 122.2) 120.2 (115.2– 125.2) 116.1 (110.6– 121.6)
HR delta (bpm) 42.2 (39.2– 45.1) 42.1 (36.2– 48.0) 36.7 (30.6– 42.8)
RR resting (bpm) 15.5 (14.8– 16.1) 15.0 (13.9– 16.2) 15.9 (14.9– 16.9)
RR exercise (bpm) 27.9 (26.8– 29.0) 28.3 (26.0– 30.7) 32.4 (25.1– 39.7)
RR delta (bpm) 12.5 (11.6– 13.4) 13.4 (11.5– 15.4) 16.5 (9.3– 23.8)
BP systolic (mmHg) 139.7 (137.3– 142.2) 140.0 (135.5– 144.6) 137.7 (133.3– 142.1)
BP diastolic (mmHg) 87.3 (86.0– 88.5) 87.9 (84.9– 90.9) 86.4 (84.2– 88.7)
Note: Delta signifies the difference between resting and exercise values. Independent t- tests for continuous 
(mean, 95% confidence interval) variables.
*p ≤ 0.05. 
T A B L E  4  Physiological and AMS data 
from 5300 m (Everest Base Camp)
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88.5 versus 89.6% (p = 0.02; Table 5). Similarly, those who 
suffered mild or moderate- to- severe AMS during the trek 
had lower end- exercise SpO2 at 3500 m; 82.2 versus 83.8% 
(p = 0.027) and 81.5 versus 83.8% (p < 0.001) respectively. 
Also, participants who experienced mild AMS had lower 
end- exercise RR at 3500 m (19.2 vs. 21.3 breaths per min-
ute, p = 0.017), in keeping with a reduced hypoxic ventila-
tory response, consequent low SpO2 and an increase in delta 
SpO2. Participants who went on to require acetazolamide had 
a higher resting RR at 3500 m (14.4 vs. 13.3 breaths per min-
ute, p = 0.047).
3.6 | Logistic regression analysis
A logistic regression analysis model was conducted to pre-
dict moderate- to- severe AMS for participants ascending to 
high altitude. A univariate regression analysis was under-
taken for each physiological variable at 3500 m and demo-
graphic variables for moderate- to- severe AMS. Variables 
with a univariate significance p < 0.15 were then included in 
a multiple logistic regression analysis.
The variables included were resting SpO2, end- exercise 
SpO2, resting RR, end- exercise RR, delta HR, systolic blood 
pressure and no previous altitude exposure >5000 m. Despite 
delta SpO2 being a significant variable in the univariate 
analysis, it was excluded in the multivariate analysis due to 
the prior inclusion of both resting and end- exercise SpO2 to 
avoid perfect multicollinearity. The prediction success was 
72.6% and the included variables improved the model from 
65.1% predicted successfully from the constant alone. End- 
exercise SpO2 and no previous exposure to altitude >5000 m 
contributed significantly to the model (p- values <0.001 and 
0.003, OR 0.870 and 2.740 respectively; Table 6). The ROC 
curve for the moderate- to- severe AMS logistic regression 
model had an area under the curve of 0.735 (95% CI 0.667– 
0.804, p < 0.001) confirming the strong predictive value of 
the model (Figure 5).
4 |  DISCUSSION
We have described the changes in daily physiological meas-
ures in a large cohort of adult volunteers ascending on an 
identical ascent profile to 5300 m over a period of 11 days. 
Along with this, we have demonstrated the potential value of 
a short step- exercise test conducted at moderate high altitude 
in predicting the development of AMS.
In keeping with the expected physiological changes with 
ascent to altitude, we observed a decrease in SpO2 and an 
increase in respiratory rate (both at rest and following ex-
ercise) throughout the ascent. This was accompanied by 
an increase in resting HR and an initial increase in post- 
exercise HR, followed by a decrease as further altitude was 
gained.
A high proportion of participants (73.5%) suffered 
AMS during the trek using the original Lake Louise 
criteria and a threshold of ≥3 with a headache. This is 
similar to the reported incidence of AMS on Kilimanjaro 
(5895  m; Karinen et al., 2008) but higher than previ-
ously reported in the same region of Nepal (Hackett et al., 
1976). This is surprising given the relatively slow ascent 
profile in this study (11 days to EBC), which is more con-
servative than many EBC trek profiles (Hackett et al., 
1976). In our study, the Lake Louise score was recorded 
daily, in the presence of investigators and a medical team, 












SpO2 resting 89.6 (89.0– 90.3) 89.5 (88.6– 90.4) 88.5
* (88.0– 89.1) 89.2 (88.7– 89.6) 88.4 (87.5– 89.3)
SpO2 exercise 83.8 (82.8– 84.9) 82.2
* (81.2– 83.2) 81.5* (80.9– 82.1) 82.4 (81.9– 82.9) 81.9 (80.8– 83.0)
SpO2 delta −5.8 (4.9– 6.7) −7.3
* (6.2– 8.3) −7.1* (6.5– 7.7) −6.8 (6.3– 7.3) −6.6 (5.5– 7.6)
HR resting 76.1 (73.2– 79.1) 74.0 (71.1– 76.9) 73.8 (71.8– 75.8) 74.9 (73.3– 76.5) 72.6 (69.4– 75.7)
HR exercise 125.0 (121.3– 128.7) 124.0 (120.4– 127.7) 126.5 (124.0– 129.0) 125.6 (123.6– 127.5) 125.3 (120.9– 129.6)
HR delta 48.9 (44.7– 53.0) 50.1 (46.1– 54.0) 52.7 (50.1– 55.3) 50.7 (48.6– 52.9) 52.4 (48.0– 56.8)
RR resting 14.2 (13.3– 15.1) 13.0 (12.1– 13.9) 13.3 (12.8– 13.9) 13.3 (12.8– 13.7) 14.4* (13.3– 15.4)
RR exercise 21.3 (20.1– 22.5) 19.2* (18.1– 20.4) 20.0 (19.2– 20.8) 19.9 (19.3– 20.6) 21.2 (19.7– 22.6)
RR delta 7.1 (6.2– 8.0) 6.2 (5.4– 7.1) 6.6 (5.9– 7.4) 6.7 (6.1– 7.2) 6.7 (5.3– 8.2)
BP systolic 136.4 (132.3– 140.5) 132.8 (129.3– 136.3) 132.3 (130.0– 134.6) 133.8 (131.8– 136.1) 132.4 (128.7– 136.1)
BP diastolic 83.7 (81.9– 85.6) 84.6 (82.5– 86.8) 83.2 (82.0– 84.4) 83.7 (82.6– 84.7) 83.7 (81.7– 85.7)
Note: Delta signifies the difference between resting and exercise values. AMS (Lake Louise score 3– 4 or ≥5) which occurred at any point throughout the trek. 
Independent t- tests (mean (95% confidence interval)). ACZ, acetazolamide use at some point during the trek.
*p ≤ 0.05. 
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potentially increasing the likelihood of detecting AMS 
when compared to other study designs. In previous stud-
ies in Nepal, the AMS scores have been recorded less fre-
quently which may have underestimated the incidence of 
AMS (Hackett et al., 1976). Furthermore, previous stud-
ies reporting the incidence of AMS in Nepal have either 
been cross- sectional (i.e. recording the incidence at a spe-
cific altitude; Basnyat et al., 1999) or did not control the 
subject ascent profile (Richalet et al., 2012). The ascent 
profile in our study was tightly controlled and thus the 
AMS rates reflected variability in individual susceptibil-
ity to AMS rather than different rates of hypoxic exposure. 
Intercurrent illnesses or the impact of other studies being 
conducted during the Xtreme Everest expedition (e.g. 
maximal cardio- pulmonary exercise testing) may have 
contributed to the high incidence of AMS. Mild AMS oc-
curred in 23.2% of participants versus moderate– severe 
AMS in 50.3%, suggesting significant pathophysiology in 
the majority of those developing AMS.
For a number of reasons, we chose to report the findings 
of this study according to the original Lake Louise criteria 
(Roach et al., 1993), rather than the revised 2018 criteria 
(Roach, 2018). Ethical committee approval was for the use 
of the original criteria and each of the expedition's medical 
teams used this framework for the detection and treatment 
of AMS. Furthermore, this was the standard criteria at the 
time of data collection and using it allows this large dataset 
to be compared to important published work in this field. It 
is likely that future research expeditions to high altitude will 
need to adopt the 2018 criteria.
There was no difference in the incidence of AMS be-
tween participants stratified by gender, age, weight or BMI. 
This is in contrast to previous studies that have reported that 
being young, female and overweight are risk factors for AMS 
(Honigman et al., 1993; Richalet et al., 2012; Ri- Li et al., 
2003). Individuals who developed mild AMS were markedly 
taller (174.3 vs. 170.8 cm), which is difficult to explain from 
a physiological perspective.
Previous studies report that a history of AMS on a pre-
ceding sojourn to high altitude is a risk factor for subse-
quent AMS (Honigman et al., 1993; Richalet et al., 2012; 
Schneider & Bernasch, 2002). We found no relationship 
between previous AMS and AMS on this expedition. We 
did, however, identify that a previous successful ascent over 
5000  m was associated with a lower incidence of AMS. 
Previous altitude exposure at lesser altitudes (>3500 m but 
<5000 m) was not associated with lower AMS rates. This 
may suggest that prior exposure to very high altitude is pro-
tective against subsequent AMS, possibly through mecha-
nisms such as epigenetic modification. Alternatively, this 
may reflect the fact that trekkers who have low susceptibil-
ity to AMS (previous successful high- altitude ascents) are 
more likely to return to altitude.
The carbonic anhydrase inhibitor acetazolamide is effec-
tive for the prophylaxis of and treatment of AMS (Leaf & 
Goldfarb, 2007). In this study, treatment for AMS was de-
termined by the expedition medical team. All subjects were 
encouraged to report symptoms of AMS to their medical of-
ficer. The treatment algorithm for AMS relied on rest and 
symptomatic treatment for headache (paracetamol and ibu-
profen) in the first instance and escalation to acetazolamide 
if symptoms did not resolve or worsened. Treatment with ac-
etazolamide therefore relied on self- reporting of problematic 
T A B L E  6  Logistic regression analysis for physiological data at 
3500 m and prediction of AMS throughout the trek
Predictor (variables with p < 0.15 
in univariate Logistic Regression 
analysis)
AMS (LLS ≥5)
Odds ratio (95% CI)
Resting SpO2 0.963 (0.880– 1.055)
Exercising SpO2 0.870
* (0.803– 0.943)
Resting respiratory rate 0.955 (0.877– 1.041)
Exercising respiratory rate 0.970 (0.912– 1.030)
Systolic blood pressure 0.988 (0.971– 1.006)
Delta SpO2 Not provided
Delta heart rate 1.016 (1.000– 1.033)
No previous altitude exposure >5000 m 2.740* (1.395– 5.384)
*p ≤ 0.05. 
F I G U R E  5  Receiver operator characteristics curve for the 
moderate to severe AMS logistic regression model. Independent 
variables included: Resting SpO2, end- exercise SpO2, resting 
respiratory rate, end- exercise respiratory rate, systolic blood pressure, 
delta heart rate and no previous altitude exposure >5000 m. Area 
under the curve = 0.735 (95% CI 0.667– 0.804, p < 0.001)
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symptoms and not Lake Louise Score alone. Only 19% of 
participants required treatment with acetazolamide, despite 
53% self- reporting moderate- to- severe AMS symptoms on 
the Lake Louise Score. Participants who were treated with 
acetazolamide were significantly older than those who were 
not (47.0 vs. 42.2  years respectively). This may reflect an 
increase in severity in older participants or reduced symptom 
tolerance.
4.1 | The Xtreme Everest step- test
In addition to resting physiological measurements, par-
ticipants underwent a daily standardised step- test exer-
cise challenge. We reported data from 3500 m (day 2) to 
5300 m (day 11) to explore relationships between physi-
ological variables during the exercise challenge and AMS 
incidence and to identify whether the response to the ex-
ercise challenge at 3500 m could predict AMS during the 
ascent.
In keeping with previous studies, we found that partic-
ipants who developed mild or moderate- to- severe AMS 
had significantly lower resting and end- exercise SpO2 
(Burtscher et al., 2004; Faulhaber et al., 2014; Guo et al., 
2014; Karinen et al., 2010; Mandolesi et al., 2014). Subjects 
with mild AMS also had significantly lower end- exercise 
RR, which may reflect a reduced hypoxic ventilatory re-
sponse. A reduced hypoxic ventilatory response and low 
post- exercise SpO2 have previously been reported to predict 
AMS risk (Richalet et al., 2012). Richalet and colleagues, 
in a large prospective cohort study, reported that greater 
desaturation and low ventilatory response during exercise 
in an acute normobaric hypoxic challenge at sea level were 
independent predictors of subsequent severe high- altitude 
illness (Richalet et al., 2012). Participants in this study 
were tested at sea level and then undertook independent 
excursions to a minimum altitude of >4000 m for three or 
more days, with a minimum overnight sleeping altitude of 
>3500  m. A questionnaire was used by subjects to self- 
report their ascent profile and physical symptoms of severe 
high- altitude illness (SHAI) using Hackett's AMS score. 
The study had a number of limitations including the use 
of unaccompanied ascents to altitude, a low response rate 
(33.2%) leading to risk of selection bias and self- evaluation 
of SHAI symptoms without medical guidance risking clas-
sification bias.
The use of delta SpO2 (before and after exercise) as a pre-
dictive measure of AMS was also supported by Karinen and 
colleagues (Karinen et al., 2010). They found that desatu-
ration after exercise at 3500  m was greater in participants 
who subsequently developed AMS at 4300 m. However, this 
relationship was not reproducible at other altitudes (Karinen 
et al., 2010). Rathat et al. also found, in a retrospective study, 
that participants who were the most clinically susceptible to 
AMS had abnormal cardiac and respiratory responses to hy-
poxia at rest and especially during exercise, thus allowing 
identification of high- risk participants (Rathat et al., 1992). 
This was in agreement with Richalet et al. who found that 
a ≥22% drop in SpO2 after a short exercise test was an in-
dependent predictor of severe high- altitude illness (Richalet 
et al., 2012). We have demonstrated that a lower SpO2 after 
a standardised exercise test at 3500 m predicted AMS devel-
opment. The absolute difference in SpO2 between those with 
and without AMS, however, was small (between 1.1% and 
2.3% mean absolute difference for resting and post- exercise 
SpO2 for those with no AMS and with moderate- to- severe 
AMS). Therefore, while the data point towards clear phys-
iological processes that may be associated with the devel-
opment of AMS, it may be of limited practical utility for 
screening an individual.
A multivariate regression analysis was undertaken to 
assess the ability of demographic variables and data from 
the XEST at 3500  m to predict moderate- to- severe AMS 
at any point during the ascent. The presence of AMS using 
a threshold of a Lake Louise score of ≥3 was felt to have 
insufficient specificity (i.e. a high false- positive rate) for 
this model. We were able to predict the risk of moderate- to- 
severe AMS using physiological variables from the step test 
(resting and end exercise SpO2, resting and end exercise RR, 
delta HR and systolic blood pressure) and previous altitude 
exposure history. This has potential utility in identifying at 
risk trekkers, who may benefit from a slower subsequent 
ascent profile, or pharmacological prophylaxis for AMS. 
Further studies are needed to identify whether performance 
in the step test in simulated altitude at sea level is of ben-
efit in identifying at risk individuals on a subsequent stan-
dardised ascent.
4.2 | Strengths and limitations
A key strength of this study was the large sample size and 
tightly controlled ascent profile. The comparison between 
participants is therefore not confounded by the magnitude 
or rate of ascent. Furthermore, measurement bias was mini-
mised by blinding all subjects to their measurements and 
strictly controlling the testing conditions (standardised rest 
before the test, standardised timing of testing and supervi-
sion by trained group leader). Additionally, no prophylactic 
medications for AMS were taken and acetazolamide use was 
reserved for those who reported symptoms of AMS to the at-
tendant medical team.
There were, however, a number of limitations to this 
study. Trekkers were recruited using website and social 
media adverts that may have led to selection bias. For exam-
ple, individuals who have previously suffered AMS may be 
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less likely to volunteer to return to altitude. Participants had 
to self- finance the expedition which is likely to have limited 
access to the trek for those in lower socio- economic groups. 
Importantly, XEST data from 3500 m were used to predict 
the development of AMS; an altitude where 26.2% of par-
ticipants had already developed AMS. Analysis of data from 
a lower altitude may have mitigated this potential confound-
ing factor. Finally, symptoms were self- evaluated which may 
have led to classification bias when determining the Lake 
Louise score.
5 |  CONCLUSIONS
In a large cohort study of participants undertaking a tightly 
controlled ascent profile to high altitude, we have demon-
strated a higher than previously reported incidence of AMS. 
Participant characteristics previously shown to predict AMS 
(gender, age, weight and history of AMS) were not related to 
the development of AMS in this study. A simple, standardised 
step test performed at 3500 m was predictive of moderate- 
to- severe AMS during the ascent. Previous extreme altitude 
exposure (>5000  m) was protective. This simple step test 
requires further validation both at high altitude and during 
pre- trek simulated altitude to evaluate its utility in identifying 
individuals more likely to develop AMS.
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